Comparison of the ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (XienceTM) in Acute ST-Elevation Myocardial Infarction
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Myocardial infarction; Thrombosis; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms TROFI-II
- 10 Aug 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.
- 23 Sep 2015 Results published in the European Heart Journal
- 12 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.